Sereno and Genmab Partner Again with a US$215 M Deal
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 63 (Table of Contents)
Published: 5 Sep-2005
DOI: 10.3833/pdr.v2005.i63.630 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Genmab granted Sereno the exclusive worldwide rights to develop and commercialize Genmab’s Phase III drug, Humax-CD4 (zanolimumab) used for treating cutaneous T-cell lymphoma...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS